drug · small molecule
adagrasib
Marketedupdated 6mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 1 investigational indication.
indications
investigational
NSCLCBreast CancerColorectal Cancer
targets
GTPase KRas
all catalysts(0)
nothing on the calendar yet
Trials studying adagrasib
- phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- phase3Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- phase3A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- phase3A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
- phase1A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- phase1KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- phase2Genetic Testing in Guiding Treatment for Patients With Brain Metastases
- phase1Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 12, 2027
~1.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Aug 21, 2043formulationUS 12383503
- Sep 10, 2041compositionUS 12281113
- Feb 5, 2041method-of-use (U-3953)US 12336995
- May 17, 2037compositionUS 10689377
FDA exclusivities (2)
- Dec 12, 2029ODE-352Orphan Drug (7y)3.1y
- Dec 12, 2027NCENew Chemical Entity (5y)1.1y
News(9)
- From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data dramaEvery ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly anticipated phase 3 data for Moderna and Merck & Co.’s cancer vaccine were leaked…fiercebiotech · 21d ago
- ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ dataAt one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.biopharma_dive · 21d ago
- ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivalsRoche has shed more light on its investigational KRAS G12C inhibitor’s phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati.fiercebiotech · 24d ago
- Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio. FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer las…endpoints · 2mo ago
- GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer assetGSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.fiercebiotech · 2mo ago
- Bristol Myers details Krazati confirmatory study failure in colorectal cancerWhile Americans geared up for the July 4 holiday, Bristol Myers Squibb laid out how a confirmatory trial for its drug Krazati failed in colorectal cancer. Patients taking Krazati plus another drug,…endpoints · 4mo ago
- Roche KRAS drug succeeds in head-to-head lung cancer studyThe Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.biopharma_dive · 4mo ago
- ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancerHighly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.biopharma_dive · 5mo ago
- Krazati fails confirmatory trial in colorectal cancer, putting approval at riskBristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated a…endpoints · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that